Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 611 to 620 of 1443 total matches.
Ivabradine (Corlanor) for Heart Failure
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
in the SHIFT trial were
76
The Medical Letter ® Vol. 57 (1469) May 25, 2015
bradycardia, hypertension ...
The FDA has approved ivabradine (Corlanor – Amgen)
to reduce the risk of hospitalization for worsening heart
failure in adults with stable, symptomatic chronic heart
failure with left ventricular ejection fraction (LVEF) ≤35%
who are in sinus rhythm with a resting heart rate ≥70
beats per minute and who are on maximum tolerated
doses of beta blockers or have a contraindication
to beta blocker use. Ivabradine has been available
internationally for years as Procoralan and Corlentor
for treatment of stable angina and heart failure.
Omacetaxine (Synribo) for CML (online only)
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
of this material is strictly prohibited.
For further information call: 800-211-2769
e81
The Medical Letter ® Vol ...
The FDA has approved omacetaxine mepesuccinate
(Synribo – Teva), a cephalotaxine known for many
years as homoharringtonine, for treatment of adults
with chronic or accelerated phase chronic myeloid
leukemia (CML) who are no longer responding to, or
who could not tolerate, two or more tyrosine kinase
inhibitors.
Afatinib (Gilotrif) for Advanced Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
-2769
e83
The Medical Letter ® Vol. 57 (1469) May 25, 2015
DOSAGE, ADMINISTRATION, AND COST ...
The FDA has approved afatinib (Gilotrif — Boehringer
Ingelheim), an oral epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, for first-line treatment
of patients with metastatic non-small cell lung cancer
(NSCLC) whose tumors have EGFR exon 19 deletions
or exon 21 (L858R) substitution mutations. These
mutations occur in about 10% of patients with NSCLC.
Afatinib is the second EGFR inhibitor to be approved
for first-line treatment of advanced lung cancer. The
first was erlotinib (Tarceva), which is also approved
for treatment of patients with locally advanced...
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
in a 4-week starter pack.
The Medical Letter ® Vol. 57 (1468) May 11, 2015
ADVERSE EFFECTS — Injection ...
The FDA has approved a pegylated form of interferon
beta-1a (Plegridy – Biogen) for biweekly treatment of
patients with relapsing multiple sclerosis (MS).
Extended-Release Hydrocodone (Hysingla ER) for Pain
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
and will be available soon.
72
The Medical Letter ® Vol. 57 (1468) May 11, 2015
associated with sensorineural hearing ...
The FDA has approved a second extended-release (ER)
formulation of the oral opioid agonist hydrocodone
(Hysingla ER – Purdue) for management of pain severe
enough to require continuous long-term therapy and
for which alternative treatment options are inadequate.
Hysingla ER tablets have abuse-deterrent properties
to discourage their misuse.
Concentrated Insulin Glargine (Toujeo) for Diabetes
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
nocturnal
hypoglycemia between week 9 and month 6.
70
The Medical Letter ® Vol. 57 (1468) May 11, 2015 ...
The FDA has approved Toujeo (Sanofi), a more
concentrated form of insulin glargine containing 300
IU/mL compared to the 100 IU/mL in Lantus (Sanofi).
Lantus is nearing the end of its patent protection in the
US, and biosimilars are expected to become available.
Testosterone Nasal Gel (Natesto) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
) in each nostril.
74
The Medical Letter ® Vol. 57 (1468) May 11, 2015
1. FDA drug safety communication ...
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first intranasal
testosterone to become available in the US. Like other
testosterone products, it is classified as a schedule
III controlled substance. The FDA recently cautioned
against using testosterone to treat low testosterone
levels solely due to aging because the benefits and
safety of such use have not been established, and there
is a possible increased risk of myocardial infarction...
Ramucirumab (Cyramza) for Gastric and GEJ Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
prohibited.
For further information call: 800-211-2769
e75
The Medical Letter ® Vol. 57 (1468) May 11 ...
Ramucirumab (Cyramza – Lilly), a monoclonal antibody
that inhibits vascular endothelial growth factor
receptor 2 (VEGFR2), has been approved by the FDA for
use as monotherapy or in combination with paclitaxel
for treatment of advanced or metastatic gastric or
gastroesophageal junction (GEJ) adenocarcinoma
that has progressed on or after platinum- or
fluoropyrimidine-based chemotherapy. Ramucirumab
is also approved for use in combination with docetaxel
(Taxotere, and others) for treatment of metastatic
non-small cell lung cancer that has progressed on or
after platinum-based...
Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia and Non-Hodgkins Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
information call: 800-211-2769
e75
The Medical Letter ® Vol. 57 (1468) May 11, 2015
1. M Hallek. Chronic ...
The FDA has approved idelalisib (Zydelig – Gilead),
an oral kinase inhibitor, for use in combination with
rituximab (Rituxan) for treatment of relapsed chronic
lymphocytic leukemia (CLL). It is also approved as
monotherapy for treatment of relapsed follicular
lymphoma and relapsed small lymphocytic lymphoma
(both are subtypes of indolent non-Hodgkins
lymphoma) in patients who have received at least two
prior systemic therapies.
Carbidopa/Levodopa Extended-Release Capsules (Rytary)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
% unchanged
Half-life (terminal) ~2 hours ~2 hours
60
The Medical Letter ® Vol. 57 (1467) April 27, 2015 ...
The FDA has approved a new formulation of carbidopa/levodopa (Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).